Skip to content

Impact of Meditation on Improving Quality of Life Among Glaucoma Patients: An Electronic Pilot Feasibility Study

Impact of Meditation on Improving Quality of Life Among Glaucoma Patients: An Electronic Pilot Feasibility Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05697094
Enrollment
100
Registered
2023-01-25
Start date
2023-11-01
Completion date
2024-12-30
Last updated
2023-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Depression, Glaucoma, Quality of Life, Sleep Disorder

Keywords

Health-related quality of life, Glaucoma, Meditation

Brief summary

Glaucoma is a chronic disease that causes loss of vision and potentially blindness as a result of optic nerve damage due to increased intraocular pressure. Currently, it is the leading cause of irreversible blindness worldwide1. In 2020, 4.1 million and 3.6 million adults over the age of 50 suffered from mild to severe visual impairment and blindness respectively induced by glaucoma1. However, these predictions are likely underestimated since glaucoma can remain asymptomatic until later stages in disease progression2. There is a convincing body of evidence suggesting that there is a linear relationship between visual impairment and decreased quality of life (QOL) among glaucoma patients3. Furthermore, evidence from The National Health and Aging Trends Study suggests that this relationship may be bidirectional where older adults with visual impairment are more likely to suffer from mental illness and older adults with mental illness are more likely to suffer from visual impairment4. Mindfulness-based meditation is a promising non-pharmacological treatment that has been shown to reduce intraocular pressure and improve QOL in patients with glaucoma5. A feasibility study will be conducted using a mixed-method design to assess the feasibility of delivering a meditation intervention online to enhance the QOL and mental health of glaucoma patients. Participants will be recruited and randomized in blocks of 10 and will undergo 1:1 randomization to the intervention arm or usual care arm. The purpose of this block randomization technique is to minimize the wait time between patient recruitment and study initiation. Participants in each arm will complete online questionnaires at patient recruitment, weeks 1, 3, 6, and 12 to measure self-reported health, depression symptoms, anxiety, and sleep quality using REDCap, an electronic data capturing system provided by Lawson Health Research Institute (LHRI).

Interventions

BEHAVIORALMeditation to Remove Stress and Create A Proper System in Mind

Meditation to Remove Stress and Create A Proper System in Mind is a guided meditation.

Sponsors

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
65 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Patients diagnosed with mild glaucoma. 2. Patients aged 65-75. 3. Being able to provide valid informed consent to participate in the research study. 4. Being able to read and understand English. 5. Having no significant self-reported or physician-diagnosed mental health disorder. 6. Able to independently access a computer to participate in virtual meditation sessions. 7. Must be able to sit comfortably for 30-35 minutes without any major pain or discomfort, can hear well enough to follow verbal instructions when the eyes are closed, and be in good general physical health.

Exclusion criteria

1. Inability to provide valid informed consent. 2. Significant communication barriers or lack of English proficiency that prevents participants from completing the questionnaires. 3. Severe depression as confirmed by a CES-D ≥ 24. 4. Having a lifetime diagnosis of self-reported other serious mental disorders, including bipolar I or II disorder, primary psychotic disorder (schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder). 5. Self-reported substance abuse or dependence within the past 3 months. 6. Having acutely unstable medical illnesses, including delirium or acute cerebrovascular or cardiovascular events within the last 6 months. 7. Having irreversible vision loss that prevents one from completing the questionnaires. 8. Participation in a study involving similar techniques.

Design outcomes

Primary

MeasureTime frameDescription
The 12-item short form surveyWeek 1, week 3, week 6, week 12The 12-Item Short Form Survey (SF-12) is a questionnaire that measures self-reported health. Scores are calculated by converting the sum of responses to a scale from 0 to 100 where a higher score indicates superior health. In addition, results can be summarised using the physical component summary (PCS) score and the mental component summary (MCS) score.

Secondary

MeasureTime frameDescription
DepressionWeek 1, week 3, week 6, week 12Depression is a feeling of severe despondency and dejection. Depression will be measured using the Center for Epidemiological Studies - Depression (CES-D) score. The CES-D provides scores from 0 to 60. Higher scores indicate worse outcome.
AnxietyWeek 1, week 3, week 6, week 12Anxiety will be measured using Hospital Anxiety and Depression Scale - Anxiety (HADS-A) subscale. The HADS-A provides scores from 0-21. Higher scores indicate worse outcome.
Sleep qualityWeek 1, week 3, week 6, week 12Sleep quality as measured using the Pittsburgh Sleep Quality Index (PSQI) scores. The PSQI provides scores from 0-21. Higher scores indicate worse outcome.

Countries

Canada

Contacts

Primary ContactMonali Malvankar, PhD
monali.malvankar@schulich.uwo.ca5196858500

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026